Facial Emotion Processing {#S1}
=========================

The ability to recognize and identify emotional cues in other people is a crucial component of human communication and interaction. In fact, deficits in emotion recognition are associated with poor social competence, interpersonal functioning, and reduced quality of life ([@B98]).

Especially faces are complex, concrete, and socially significant stimuli that are linked to emotional reactions ([@B83]). Moreover, human faces hold a natural salience and attract attention more than other visual stimuli ([@B66]). Hence, facial stimuli are widely used in studies assessing emotion processing under various conditions and in different clinical disturbances. In contrast to emotional prosodic stimuli, they are independent from language and thus offer the possibility to render comparability across different countries and languages. In fact, Ekman postulated basic emotions that are independent from literate culture and can be identified cross-culturally in facial expressions. Accordingly, pictures of emotional facial expression are a widely used tool in research on affective (neuro)sciences. The Ekman faces ([@B35]) are the oldest but still used database, but other face databases have been constituted in research studies, for instance, the Karolinska databases ([@B73]), PENN Facial Discrimination Test ([@B38]), or NimStim ([@B113]).

However, facial stimuli are somehow static and unnatural, as people usually encounter moving and dynamic faces in daily life. Moving facial stimuli are advantageous over static ones because they can be recognized easier and faster, especially for rather seldom and culture-defined emotional expressions as pride or defiance, presumably because photographs contain no dynamic information that helps identifying facial expressions ([@B61]). Moreover, dynamic faces lead to more widespread neural activation patterns and also arouse cortical regions associated with higher social relevance ([@B100]; [@B114]).

To a certain degree, the processing of facial stimuli underlies some attentional biases. Fearful, angry, or generally threatening faces are detected faster than neutral ones ([@B59]; [@B109]) in accordance with the evolutionary point of view of a faster processing of threatening or possibly life-endangering stimuli. A facilitation of visual search tasks to identify fear-related pictures among fear-irrelevant ones was demonstrated ([@B85]), as well as slower attention disengagement from angry faces compared to neutral or happy ones ([@B42]). The "automatic vigilance" hypothesis implies that people tend to focus their attention preferentially on negative stimuli and can also rather difficult dissolve it from them ([@B121]; [@B85]). However, there are also hints that postulate an advantageous processing of positive stimuli, that is, words and facial expressions ([@B67]; [@B55]; [@B64]; [@B118]). Thus, decoding and interpreting emotions displayed in facial expressions, especially those with negative valence, play a fundamental role in human interactions.

Another interesting factor when investigating facial emotion processing is the task type used in a study. Emotion processing can be assessed by identification tasks in which participants are requested to select an appropriate label for a given emotion. In contrast, in discrimination or matching tasks, one has to judge whether or not two faces express the same emotion. These different forms of emotion recognition also reflect different and successive processing stages. Both recognition processes occur relatively early after stimulus presentation. But while the perception if two faces are identical happens rather automatic and unconsciously, that is, in an implicit way, identification tasks require additional knowledge and conscious deliberation of facial expression information as they rather involve explicit emotional processing. Hence, implicit emotional processing refers to the automatic and involuntary processing of emotional stimuli that a person is confronted with (e.g., pictures or voices). In contrast, explicit processing is the downstream process afterward that requires cognitive abilities (e.g., concentration, attention) to process and classify these given emotional stimuli.

Both forms of emotion processing may be differentially compromised in patients with Parkinson's disease (PD), as will be shown in *Recognition of Facial Emotion in Parkinson's Patients* of this review. Subthalamic stimulation may further have the potential not only to influence emotional recognition out of facial expressions but also to affect implicit and explicit emotional processing in a distinct way. In the following sections of this review, we will point out findings on facial emotional processing in PD patients. Then, we will focus on how subthalamic stimulation may impact those processes and, finally, discuss methodological differences between studies.

Recognition of Facial Emotion in Parkinson's Patients {#S2}
=====================================================

Parkinson's disease is a neurodegenerative disease characterized by increasing motor impairments, such as tremor, rigidity, and bradykinesia due to a depletion of dopaminergic neurons in the striatum. While PD patients occasionally suffer from motor impairments in daily life, a spectrum of concomitant non-motor symptoms including changes in mood, impulsivity, and other neuropsychiatric aspects, as well as deficits in cognitive and emotional processing have the potential to considerably influence subjective well-being and quality of life in patients ([@B71]; [@B97]; [@B10]; [@B1]).

In the 1980s, it was first suggested that PD patients also suffer from a selective impairment in facial emotion recognition ([@B12]; [@B16]). Since then, this observation has been replicated in a vast majority of subsequent studies, showing deficient facial emotion recognition in PD patients when compared to healthy controls (HC) (e.g., [@B60]; [@B61]; [@B108]; [@B125]; [@B110]; [@B69]; [@B28]). Accordingly, reviews and extended meta-analyses demonstrated deficits in facial emotion processing and outlined potentially biasing and correlated factors between studies like visuospatial or cognitive deficits, disease severity, or mood disorders of patients among others ([@B9]; [@B48]; [@B8]). In particular, emotion recognition of faces was reported to be affected in all basic emotions, but most deficits concerned the recognition of negative emotions ([@B8]). In contrast, however, other studies did not reveal any deterioration in emotion processing in PD ([@B74]; [@B3]; [@B21]; [@B88]).

It was suggested that emotion recognition deficits in PD were associated with influences of dopaminergic medication, but results are inconsistent. [@B48] reported emotion perception to be largely unaffected by medication status; other studies supported this assumption ([@B125]; [@B92]; [@B29]; [@B96]; [@B36]). Contrastingly, several publications demonstrated beneficial effects of L-Dopa on emotion recognition ([@B112]; [@B108]; [@B31]), suggesting that L-Dopa partially restores amygdala response but in dependence of disease progression ([@B32]). In fact, in the early disease stages, mesocorticolimbic pathways are described to be relatively spared compared with the motor pathway ([@B19]), and L-Dopa needed to improve motor symptoms would at the same time overdose mesolimbic projections to subcortical structures involved in emotion processing like the amygdala, leading to detrimental effects in emotion perception, whereas in later disease stages, these effects would be beneficial.

Interestingly, studies consistently demonstrating deficient emotion recognition in PD patients generally assessed explicit emotional processing by explicit evaluation and naming of the emotional value of facial expressions ([@B125]; [@B62]; [@B102]; [@B57]; [@B91]; [@B124]). Here, diminished recognition was demonstrated for specific emotions such as anger ([@B108]; [@B34]; [@B69]; [@B28]), surprise ([@B28]), fear ([@B61]; [@B108]), and disgust ([@B61]; [@B34]; [@B110]; [@B9]).

In contrast, implicit emotional recognition abilities in PD have received rather limited attention so far, and thus, implicit processing deficits are less proven. [@B122] tested implicit and explicit emotion processing by means of event-related potentials in response to affective pictures. The authors reported preserved early implicit processing but blunted explicit emotional responses in PD patients, supporting the view that the elementary--implicit--reaction to an emotion is independent from the conscious response to it. Hence, the emotional salience detection from faces may be compromised in PD while early perceptual and structural face processing appears to be intact. Two further studies investigated implicit emotional processing of pictorial and verbal affective stimuli but did not test for emotional facial expressions ([@B24]; [@B17]). In accordance, they also reported preserved implicit emotional processing in PD patients. In a previous study, we assessed explicit as well as implicit emotional processing in PD ([@B119]). For this purpose, we investigated emotion recognition of circumscribed facial information, for example, emotional states portrayed only in the eye region of a face, in an affective priming paradigm. We found largely preserved implicit (i.e., automatic and unconscious) emotional processing of facial expressions in PD patients, as shown by a preserved sensitivity to emotional priming; however, with a specific altered processing of disgust- and happiness-connoted stimuli. In contrast and consistent with the literature, explicit emotional processing was considerably impaired for facial stimulus material in PD.

Hence, PD compromises explicit emotional processing in general, as was shown for semantic, pictorial, and facial stimuli ([@B24]; [@B17]; [@B119]), with a particular emphasis on facial emotion recognition due to its significance in social contexts. However, the ability to be implicitly sensitive to emotional content seems to be largely spared by the disease, especially for facial stimuli.

Yet, the presented studies on facial emotional processing in PD differ with respect to several methodological, clinical, and patients' individual factors and thus lack direct comparability. Because of this high variability in studies, several confounding factors need to be considered. In their meta-analysis, [@B48] pointed out seven potential moderators of emotional facial processing in PD that might be associated with inconsistent results of previous studies. Three of these postulated moderators concerned methodological aspects referring to the task (stimulus modality, task type, emotion displayed), and the other four relate to the patients themselves (medication status, motor disability, depression status, executive functions, and visuospatial abilities). The authors also stressed the role of potential working memory constraints during the task. [@B8] further emphasized the relevance of possible interactions between facial emotion impairments and mood disorders.

Functional neuroimaging studies investigating the neural basis of emotion recognition in healthy human subjects have proposed both the ventral striatum and the amygdala to be involved in processing of negative emotions like fear and disgust ([@B81]; [@B93]). These structures consistently receive afferents from the dopaminergic neurons of the mesolimbic ventral tegmental area, which is known to degenerate in PD. The amygdala is supposed to represent an essential factor of the emotional face processing impairments in PD ([@B18]; [@B49]; [@B126]). In a functional imaging study, [@B63] reported that the amygdala volume correlated with the ability to recognize happy facial expressions. In fact, projections from the amygdala reach the striatum, and the amygdala itself undergoes severe pathological changes during the course of PD ([@B18]). However, PD-related amygdala involvement seems to be unrelated to cognitive impairments ([@B18]), indicating that emotion processing associated with the amygdala might be spared even with ongoing PD pathology. Other attempts to explain deviant emotion processing in PD thus focus on the involvement of dopamine in emotional processing. Ongoing dopamine depletion of the mesolimbic pathway leads to a dysfunction of the limbic loop, which in turn links the basal ganglia to the orbitofrontal cortex (OFC), which leads to an impaired neuronal processing in the limbic projection area ([@B7]; [@B30]). Furthermore, the involvement of the striatum and specifically the insula in the processing of disgust was postulated ([@B107]; [@B94]; [@B23]). The insula is highly interconnected with the basal ganglia and cortical regions, interacts with multiple brain networks ([@B27]; [@B45]), and is one of the first cortical regions that is pathologically affected in PD ([@B20]). Lesions of the insula impair the recognition of facial emotions ([@B23]), and the loss of normal metabolic activity in insular neurons in PD has been associated with blunted emotions in PD patients ([@B122]; [@B95]). Finally, subcortical activation of the thalamus, putamen, and basal ganglia during emotional processing was observed in several functional MRI (fMRI) studies ([@B82]; [@B99]; [@B26]), demonstrating involvement of the basal ganglia in emotion processing.

Another approach to explain diminished emotion processing in PD patients has been discussed. According to the *simulation theory of emotions*, some authors assume the contribution of motor impairments to the emotion recognition deficit ([@B47]; [@B84]). PD-inherent symptoms like facial amimia and dysprosody have been discussed as being partially responsible for the patients' inaccuracy in emotion recognition, but other investigations report contradictory results (see [@B9], for a review).

Influence of Subthalamic Stimulation on Facial Emotion Processing in PD {#S3}
=======================================================================

Method {#S3.SS1}
------

We conducted a detailed search of literature with the aim of reviewing all of the relevant papers on STN-DBS influence on facial emotion processing in PD patients. We searched PubMed services (April 2019) with the following keywords: *Parkinson's disease, deep brain stimulation, subthalamic stimulation, emotion recognition*, *emotion processing*, *face*, and *facial expression*. We also hand-searched relevant journals and examined the references of retrieved key articles to find possible further publications regarding facial emotion processing. This review particularly focused on reported comparisons between both DBS conditions (ON and OFF) and thus aims to report within-group differences between both measure conditions. Furthermore, only those publications were chosen that explicitly reported patients' performances on emotion recognition out of faces or facial stimuli, at least as a subtask among other tests. Articles were restricted to the English language and were published between 2003 and 2019. Nineteen publications fulfilled the abovementioned criterions and were identified as being relevant to the question of how STN-DBS influences facial emotion recognition in patients ([Table 1](#T1){ref-type="table"}).

###### 

Influence of STN-DBS on recognition of emotional facial expressions in PD patients.

              ***N***                                                            **Disease duration**   **L-dopa therapy**   **Experimental design**                                          **Task**                                                                                                      **Emotional stimuli**                                                           **Results**
  ----------- ------------------------------------------------------------------ ---------------------- -------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B101]     12 PD                                                              17.0 ± 6.3 years       Yes                  Med only; Med-off/DBS-OFF; Med-off/DBS-ON                        Discrimination                                                                                                PENN facial discrimination test ([@B38])                                        •No stimulation effects on emotion discrimination;but mood-enhancing effect and improved emotional memory under DBS
  [@B104]     10 PD                                                              16 ± 3.1 years         Yes (except 1)       DBS-OFF; DBS-ON                                                  Identification                                                                                                FEEST (facial expressions of emotions: stimuli and test) ([@B127])              •Reduced recognition of angry expressions during DBS•No changes in facial emotion processing for all other emotions
  [@B34]      12 PD, 12 HC                                                       13 ± 2.5 years         Yes                  DBS-OFF (pre-surgically); DBS-ON (3 months after surgery)        Intensity rating of expressions on emotion rating scales                                                      Emotional facial expressions from [@B53]                                        •General impairment in facial emotion decoding after surgery in 9/12 patients•Significant post-operative impairment for sadness, anger, and a trend for disgust
  [@B15]      15 PD (post-operative group), 15 PD (preoperative group), 15 HC    15 ± 6.2 years         Yes                  DBS-OFF; DBS-ON                                                  Identification                                                                                                [@B35]                                                                          •Specific impairment to recognize fear in the tested post-operative group compared to preoperative group and HC;but no difference between DBS-ON and DBS-OFF within this group for all facial expressions
  [@B46]      10 PD, 22 HC                                                       13 ± 3.2 years         Yes                  DBS-OFF; DBS-ON                                                  PET study: no task, patients were instructed to look at pictures; After 1 week evaluation of "pleasantness"   EPS (Empathy Picture System)                                                    •Inhibited emotional activation of the right fusiform gyrus under DBS•DBS raised emotional activation of the anterior cingulated and lowered activity of the putamen
  [@B13]      15 PD                                                              12.0 ± 6.0 years       Yes                  Med-off/DBS-ON; Med-off/DBS-OFF; Med-on/DBS-OFF; Med-on/DBS-ON   Matching                                                                                                      Computerized task consisting of pairs conveying the same or different emotion   •Changes in mood core dimensions under stimulation, but stable emotion discrimination processing
  [@B33]      17 PD                                                              11.8 ± 2.6 years       Yes                  DBS-OFF (3 months pre surgery); DBS-ON (3 months post-surgery)   Identification                                                                                                [@B35]                                                                          •Impaired fear and sadness recognition after STN-DBS•Worsened apathy scores after DBS
  [@B70]      13 PD, 30 HC                                                       10.9 ± 2.2 years       Yes                  DBS-OFF (3 months pre surgery); DBS-ON (3 months post-surgery)   Identification                                                                                                [@B35]                                                                          •Selective reduction of fear recognition under stimulation•Correlation between reduced glucose metabolism in the right orbitofrontal cortex and reduced fear recognition
  [@B89]      24 PD, 20 untreated PD (pathological control group), 30 HC         11.9 ± 2.5 years       Yes                  DBS-OFF (3 months pre surgery); DBS-ON (3 months post-surgery)   Identification                                                                                                [@B35]                                                                          •Impaired fear and sadness recognition after STN-DBS
  [@B90]      13 PD, 13 HC                                                       10.5 ± 3.6 years       Yes                  DBS-OFF (3 months pre surgery); DBS-ON (3 months post-surgery)   Identification                                                                                                RMET ([@B11])                                                                   •Reduced Emotion score for patients under DBS but unchanged results in gender attribution task
  [@B80]      14 PD, 14 HC                                                       12.3 ± 0.7 years       Yes                  Med-off/DBS-ON; Med-off/DBS-OFF; Med-on/DBS-OFF; Med-on/DBS-ON   Identification/Categorization                                                                                 Karolinska emotional faces database ([@B73])                                    •Decreased recognition of disgust under DBS (and Med-off)•No impairment in emotion recognition observed when both therapies (Med and DBS) were "ON"•Combined administration of Med and DBS has more benefit on facial emotion recognition than the separate administration of therapies alone
  [@B4]       12 PD, 13 HC                                                       10.9 ± 4.1 years       Yes                  Med-off/DBS-ON; Med-off/DBS-OFF; Med-on/DBS-OFF; Med-on/DBS-ON   Discrimination, Intensity rating of expressions on emotion rating scales                                      NimStim set ([@B113])                                                           •Process of DBS surgery (microlesions) reduced patients' performance on discrimination task independently of stimulus type•No changes in facial emotion recognition, stable performance on facial emotion discrimination after 4 months post-surgery, except for disgust
  [@B5]       30 PD                                                              15.9 ± 7.0 years       Yes                  DBS-OFF (before surgery); DBS-ON (1 years after surgery)         Matching, Identification                                                                                      CATS (Comprehensive Affect Testing System) ([@B44])                             •No changes in discrimination and naming of emotional faces under DBS
  [@B79]      14 PD, 14 HC                                                       12.4 ± 0.7 years       Yes                  Med-off/DBS-ON; Med-off/DBS-OFF; Med-on/DBS-OFF; Med-on/DBS-ON   Identification                                                                                                [@B35]                                                                          •Lower overall recognition rate for high spatial frequency emotional faces under DBS•No effect of DBS on recognition of either broad or low spatial frequency faces
  [@B78]      9 PD, 7 untreated PD (receiving Med), 23 elderly HC, 21 young HC   NA                     Yes                  Med only; DBS-OFF; DBS-ON                                        Identification                                                                                                RMET, TASIT (Awareness of Social Inference Test, face + voice), ([@B77])        •Neither therapy type (Med or DBS + Med) nor therapy state (ON/OFF) changed emotion recognition
  [@B58]      11 PD, 11 HC                                                       11.5 ± 4.2 years       Yes (except 1)       DBS-OFF; DBS-ON                                                  Emotional Stroop Task                                                                                         2D Facial Emotional Stimuli dataset ([@B38])                                    •No conflict-induced slowing under DBS•Valence bias affecting conflict-induced reaction time slowing under DBS-OFF
  [@B37]^∗^   18 PD, 20 untreated PD (receiving Med), 20 HC                      12.6 ± 3.0 years       Yes                  Med only; Med-on/DBS-ON                                          Identification                                                                                                [@B35]; RMET                                                                    •Comparisons only for DBS versus HC, no comparison between DBS-ON and DBS-OFF•No impairment in facial emotion recognition and in affective Theory of Mind in DBS patients compared to HC
  [@B76]      16 PD, 16 HC                                                       10.6 ± 3.4 years       Yes                  Med-off/DBS-ON; Med-off/DBS-OFF; Med-on/DBS-OFF; Med-on/DBS-ON   Emotional Stroop Task                                                                                         Karolinska emotional faces database ([@B73])                                    •For fearful faces, emotional Stroop effect was higher under dopaminergic treatment than under DBS•Both treatments did not modulate Stroop effect•EEG: L-Dopa but not DBS increases the amplitude of the event-related potential N170
  [@B117]     14 PD                                                              11.7 ± 4.4 years       Yes (except 2)       DBS-OFF; DBS-ON                                                  Affective priming paradigm, identification                                                                    [@B35]                                                                          •DBS affected explicit emotional processing more than implicit processing•DBS selectively diminished explicit processing of disgust but had an ameliorating effect on discriminating fear stimuli

∗

No within-group comparison; PD: Parkinson's disease patients; HC: healthy controls; Med: medication; DBS: deep brain stimulation.

Facial Emotion Recognition Under STN-DBS {#S3.SS2}
----------------------------------------

### Anatomical and Structural Correlates of Emotional Processing Under STN-DBS {#S3.SS2.SSS1}

Subthalamic stimulation has been variously proven to be a helpful therapeutic tool to improve motor disturbances in PD ([@B43]; [@B52], [@B51]) but has also been shown to influence cognitive domains, such as executive functions and language ([@B40]; [@B120]; [@B128]). It further plays a central role in the regulation of limbic and emotional/affective functions ([@B111]; [@B75]). The STN is part of the basal ganglia, which are interconnected to specific motor, cognitive, and limbic cortical regions through partially closed and sequentially arranged circuits ([@B6]; [@B87]). The STN is thus closely connected with the ventral striatum and ventral pallidum, as well as to limbic cortical areas such as the anterior cingulated cortex and the OFC; regions that are known to play a major role in the recognition of emotions from faces and voices ([@B2]; [@B123]) and from emotional prosody ([@B99]). DBS of the STN modifies dopaminergic transmission in the basal ganglia and thus affects the limbic, associative, and motor network circuits ([@B111]; [@B75]). Considering the anatomic overlap of the functional areas of the STN ([@B50]), stimulation of the dorsolateral motor region of the STN may as well have effects on the mesolimbic basal ganglia loops ([@B25]), leading to effects in emotion processing, for instance. In this context, STN-DBS has been described to occasionally cause neuropsychiatric effects like mood disturbances or depression ([@B14]; [@B65]). A relation between depression and emotion processing deficits has been suggested, but analyses yielded different results concerning possible interactions, suggesting emotion processing deficits not to be a consequence of depression or mood disturbances ([@B48]). [@B101] investigated the relation between mood induction and emotion recognition under STN-DBS and found a mood-enhancing effect as well as intensified emotional experience under stimulation but no changes in emotion recognition out of faces. The authors concluded that emotional recognition and categorization may involve other brain areas than those involved in the sole emotion memory or emotion experience ([@B101]).

Generally, studies investigating the effects of STN-DBS on facial emotion perception in PD demonstrated rather heterogeneous results, and either covered unchanged emotion recognition of facial expressions under DBS ([@B101]; [@B13]; [@B5]; [@B78]) or worsening of explicit discriminating emotional faces under stimulation ([@B46]; [@B89], [@B90]). Precisely, a tendency for DBS to cause deficits in facial discrimination of especially negative emotions like disgust ([@B80]; [@B4]; [@B117]), anger ([@B104]), sadness ([@B33]), and fear ([@B33]; [@B80]) was observed.

[@B4] found diminished disgust discrimination abilities under DBS for facial expressions and emotional prosodic stimuli in PD patients but emphasized that impaired disgust recognition was prominent also before DBS implant in patients, which is in line with other studies (see *Recognition of Facial Emotion in Parkinson's Patients*). Impaired processing of disgust is thus related to the neurodegenerative disease itself rather than just an impact of STN-DBS ([@B80]; [@B4]). Still, there seems to be consensus that disgust processing in faces and also in other stimulus modalities (e.g., prosody) even worsened under STN-DBS ([@B115]; [@B80]; [@B4]). Results concerning other negative emotions are not that conclusive. For instance, while some studies could demonstrate a clear deterioration of fear recognition under stimulation ([@B33]; [@B70]; [@B89]), others failed to show any worsening of fear processing under DBS (e.g., [@B104]; [@B4]; [@B78]).

There are different attempts to explain findings of reduced facial emotion processing of especially negative emotions. Previous investigations found activity modulations in brain regions associated with emotional processing during STN stimulation. PET studies in patients showed activity changes in non-motor areas of the associative and limbic circuits during STN-DBS and thus contribute to the findings of the central role the STN holds in motor, cognitive, and limbic basal ganglia circuits ([@B103], [@B105]; [@B54]). Using local field potentials, [@B68] found limbic activation of the STN in response to emotionally arousing pictures and proposed that this might be a reason for altered affect in PD patients. Several authors hence proposed impaired facial emotion recognition to be a result of a limbic dysfunction induced by STN-DBS ([@B34]; [@B15]; [@B33]). [@B70] demonstrated a correlation between impaired fear recognition under STN-DBS and a decrease in glucose metabolism in the right OFC. In their positron emission tomography (PET) study, [@B46] proposed that the stimulation of the STN would inhibit regional blood flow rate activity in the right lateral fusiform gyrus, an area that is generally activated by emotional facial expressions, leading to altered emotion perception in faces.

### Implicit and Explicit Emotional Processing Under STN-DBS {#S3.SS2.SSS2}

Most studies investigating DBS influence on emotion recognition clearly concentrated on one form of emotion processing only. Whereas nearly all studies in this review measured the explicit identification of emotional facial expressions, [@B46] rather investigated the emotional reaction of patients to the pictures displayed. Patient's general recognition of facial expressions was significantly altered by STN stimulation, whereas emotional assessment *per se* appeared to be unaffected during DBS because patients showed no significant perception changes for DBS-ON or OFF. The authors assumed that patients first needed to identify the emotional valence of a picture to subsequently assess an empathetic reaction to this picture. [@B46] hence referred to different aspects of emotional processing, pointing out intact implicit, but impaired explicit emotional processing of facial expressions under DBS. This is in line with a study measuring implicit and explicit emotional lexical-semantic processing, suggesting that basal ganglia-thalamocortical circuits are likely not to be involved in the automatic (implicit) activation of emotion evaluations ([@B24]). Basal ganglia-thalamocortical activation would be necessary if cognitive-driven decisions are requested.

This notion was seized further in the study by [@B117], in which, for the first time, DBS impact on implicit as well as explicit emotional processing in PD patients was examined. In an affective priming paradigm, the authors used emotional words and emotional circumscribed facial regions, that is, human eyes displaying different emotions. DBS affected explicit emotional processing more than implicit processing and had a considerable diminishing effect on the processing of disgust stimuli, but even improved explicit processing of fear stimuli. This study supported the assumption of the varying involvement of the basal ganglia, depending on demanded conscious or automatic stimuli perception and processing, and further stressed the existence of different neural mechanisms for different emotional expressions. As already described in *Recognition of Facial Emotion in Parkinson's Patients*, referring to studies assessing emotion processing in non-stimulated PD patients, the classification of analyses in implicit and explicit emotional processing is rather neglected in the following presented studies. Most studies in this review report data of explicit processing only. Hence, a purpose and challenge for future studies lie in the investigation of both aspects combined.

### Influence of Medication Status {#S3.SS2.SSS3}

One possible confounder that may explain differences between the reported studies is additional medication intake despite STN-DBS in patients. In all presented studies, patients received additional dopaminergic medication, which was applied supplementary to DBS (except for single patients). Some publications, however, tried to filter out L-Dopa-associated effects on facial recognition performance under DBS and deployed an experimental setting with alternating testing conditions for medication and DBS: (1) Med OFF/DBS OFF; (2) Med OFF/DBS ON; (3) Med ON/DBS OFF; (4) Med ON/DBS ON ([@B13]; [@B80]; [@B4]; [@B79]; [@B76]). Two other studies reported data for facial recognition in three different conditions: for DBS ON and OFF and for medicated patients only ([@B101]; [@B78]). Whereas [@B101] tested the identical patient group with medication only and with DBS only to ensure direct comparability, the medication group in the study of [@B78] consisted of different patients from those in the tested DBS patient group.

In general, emotion recognition was described to be unaffected by medication status, and this was even found for patients not yet treated with STN-DBS ([@B96]; [@B78]). However, different studies demonstrate that the interaction between dopaminergic medication and STN-DBS offers the best results in facial emotion recognition ([@B80]; [@B76]). To explain this finding, modifications to the non-motor basal ganglia-thalamocortical circuitry and to the emotional functions of the OFC and amygdala through DBS and L-Dopa medication have been proposed. The interaction between L-Dopa and STN-DBS plays a crucial role for patients, since in most cases, dopaminergic medication intake is continued despite DBS implant in patients. In fact, all studies presented in [Table 1](#T1){ref-type="table"} report additional levodopa intake besides STN-DBS. L-Dopa could overdose the mesolimbic projections toward the amygdala and OFC and thus lead to altered amygdala activation in response to emotion perception ([@B32]; [@B115]; [@B4]). DBS would compensate this overactivation by decreasing OFC activity and thereby restoring the necessary OFC-amygdala interaction ([@B80]). In turn, L-Dopa would compensate for the decreasing effect DBS has on the OFC and amygdala, which may explain facial recognition improvement when both therapeutic measures are "ON." Another explanation was given by [@B116], who suggested therapeutic synergism of the effects of L-Dopa and DBS. In their meta-analysis, they found that the combined effect was greater than either treatment alone, while both alone lessened motor severity in patients to a similar effect.

Moreover, neurophysiological studies could show differing regional brain activation of areas associated with facial recognition, depending on therapy means. In their EEG study, [@B76] demonstrated that the peak of the event-related potential N170, which is thought to represent facial integration and to be modulated by facial emotional content, was increased by levodopa, but not by DBS. While levodopa induced stronger activity in the right fusiform gyrus that generated the N170, STN-DBS hypoactivated this region. [@B46] used PET to compare functional activations of brain regions when processing emotional facial expressions. They found inhibited regional blood flow rates in the right fusiform gyrus under DBS, which was not prominent when stimulation was switched OFF. STN-DBS did not change fusiform reaction to emotional expressions but raised the emotional activation of the anterior cingulate and lowered the activity of the putamen.

### Methodological and Experimental Differences Between Studies {#S3.SS2.SSS4}

In general, it is difficult to draw reliable conclusions for distinct results of the single publications given the methodological and experimental differences between studies. However, one recurring finding throughout studies is that the impairment in emotion recognition in patients could not be attributed to secondary variables, such as depression, anxiety, cognitive declines, or visuospatial deficits ([@B34]; [@B104]; [@B33]; [@B5]). Hence, emotion recognition deficits are to be already associated with disease-specific mechanisms. For instance, the insula and amygdala have been shown to be involved in the processing of facial emotions ([@B107]; [@B23]) but to be involved in pathological changes due to PD, as described in *Recognition of Facial Emotion in Parkinson's Patients* of this review.

Moreover, the impairment in facial emotion recognition seems to selectively concern negative emotions, while findings on positive emotions are rather scarce or non-existing. Yet, one has to keep in mind that studies examined far more negative (fear, anger, sadness, disgust) than positively valenced emotions. Actually, only happiness serves as a positive emotion throughout all studies; some publications also included surprise, whose valence is difficult to define as positive or negative without explanatory context due to its ambiguity. Also, happiness can have distinct reasons and thus different implications and consequences. Hence, there exists a bias concerning the frequency and fluency of negative versus positive emotions because negative emotions are far more differentiated than positive ones. From the evolutionary point of view, negative emotions imply greater functional value than positive ones because they help ensure "surviving" and coping in negative situations--and are thus more noticeable than positive emotions in daily life. In accordance, the "*angry face advantage*" postulates that angry faces are detected faster than other emotional and neutral faces ([@B72]). But contrastingly, happiness seems to be easily recognized from facial expressions, which usually leads to ceiling effects in some studies ([@B61]). The described effect of a PD-inherent specific processing impairment has to be regarded and interpreted under these preliminary aspects.

Methodological differences between the presented studies concern the investigated emotions, the applied tests, as well as calculations. For this reason, it is difficult to determine if STN-DBS selectively impairs the recognition of specific emotions or if it rather leads to an overall deficit. Whereas most studies investigated multiple and different single emotions like disgust, fear, or happiness (e.g., [@B33]; [@B89]; [@B79]), other studies calculated a general overall emotion score that does not provide information about processing mechanisms for specific emotions (for instance, [@B101]; [@B13]; [@B90]; [@B78]). [@B5] reported mean values for positive and negative emotions but not for single emotions. Finally, some studies used only a small subset of two facial expressions for their investigation, like happiness and sadness/fear due to experimental settings ([@B58]; [@B76]). Also, [@B34] decided to eliminate happiness and fear expressions in their setting from the start because of methodological considerations.

Other disparities between studies refer to experimental settings and individual patients' preconditions. For example, some researchers (e.g., [@B33]; [@B89]; [@B78]) tested early progression PD patients, that is, patients with motor impairments not past Hoehn and Yahr stage II. Other studies provided data of patients with far more advanced disease progressions ([@B34]; [@B104]). All studies except [@B78] gave information about patients' disease duration \[with a range from 10.5 ± 3.6 years ([@B90]) to 17.0 ± 6.3 years ([@B101])\].

Several studies compared emotion processing of facial expressions in PD patients preoperatively and postoperatively, with DBS-OFF results gained before surgery and DBS-ON results assessed several months after surgery ([@B34]; [@B33]; [@B70]; [@B89], [@B90]; [@B5]). All of these except [@B5] reported diminished facial emotion (and prosody) recognition after DBS surgery. [@B5] did not find any differences between both measure times.

This experimental setting offers the advantage of precluding learning effects of the stimulus material due to long time intervals between both measures. But this time span of at least several months comes along with further subjective, social, and cognitive influences on patients, which cannot be taken into account when interpreting performances and might thus bias the comparability of both testing results. Plus, changes of medication doses between both testing points are common. Moreover, the DBS surgery itself as well as alterations during the operation can have impacts on the performance outcome under DBS ON, which are not present for the OFF condition. Especially [@B4] emphasized the effects of microlesions on facial recognition. They reported diminished facial emotion recognition in patients even before surgery. According to their results, soon after DBS surgery, before turning the stimulator ON, patients were impaired in facial discrimination and recognition tasks for the emotion sadness only but showed recovered ability to recognize disgust. After 4 months post-surgery, patients' performance in facial emotion recognition remained stable but impaired disgust recognition was prominent again, just like before DBS operation. The authors suggested microlesion effects in the processing of single emotions and stressed the existence of different neural mechanisms for different emotional expressions.

To face the problem of long time intervals and possible diminished comparability of OFF and ON results due to subjective and environmental influences, other studies tested performance only after patients had been operated by switching the stimulator ON and OFF post-operatively. One can assume that possible influences deriving from surgery (microlesions, releasing effects, etc.) have subsided until then and are thus comparable for both testing sessions (DBS-ON and DBS-OFF). However, surgery itself can have a considerable impact on neuropsychological and executive functioning and might provoke alterations in the processing of emotional stimulus material ([@B22]). Previously, [@B86] proposed not STN-DBS itself but rather insertion or lesion effects associated with electrode implantation as a possible underlying mechanism to explain performance differences preoperatively and post-operatively. Reliable comparisons between DBS-treated patients and HC can thus only be made with constraints. Another point that has to be kept in mind when analyzing results of emotion processing under stimulation is the fact that the long-lasting cerebral circuits reorganization following chronic STN-DBS is a long-term procedure and cannot be tackled early after turning the stimulator OFF. Hence, given results in ON/OFF testings rather shortly after DBS surgery do not represent final modulations caused by stimulation; hence, long-term analyses would be desirable in this context. As already mentioned above, general psychiatric anxiety was not associated with impaired emotion perception ([@B34]). However, the sole act of switching the stimulator ON or OFF, respectively, might lead to transient side effects but also subjective inconveniences like bad expectations and worry of experiencing returning (motor) symptoms like tremor in the hands when the stimulation is stopped. This subjectively perceived and testing situation-dependent trouble might also impact patients' performance and might actually contribute to the differing results concerning facial emotion recognition in the presented studies.

Contrary to the remaining studies reported in this review, [@B37] investigated facial emotion recognition while stimulation was ON but did not test (or did not report) results for DBS-OFF and rather demonstrated comparisons to a group of L-Dopa-treated patients without surgery and to a group of HC. It is hence difficult to draw conclusions about the efficacy and impact of STN-DBS on emotional processing in this study.

Two publications in this review adopt a special position within research of facial emotion recognition under DBS. [@B58] and [@B76] did not investigate explicit emotion recognition *per se*, but rather recognition of emotional faces during a Stroop task. Both applied a modified version of the classic Stroop test, the so-called facial emotional Stroop test developed by [@B39]. Patients were asked to recognize the emotion that was expressed by faces, while they should ignore the emotion of a word written over these faces. Hence, congruent trials would imply the same emotional valence for both face and word. The Stroop effect refers to the difference in reaction times between congruent and incongruent trials and represents a measure of the overall conflict processing. [@B76] examined "happiness," "fear," and a neutral condition, whereas [@B58] used "joy" and "grief" in their Stroop test. [@B58] reported no reaction slowing in patients under DBS, thus, demonstrating a defect in within-trial conflict adaptation induced by STN-DBS. [@B76] found that STN-DBS, in contrast to levodopa, has no significant impact on emotional conflict processing, but that PD patients suffer from a dysfunction in the early processing of facial emotions, which could be anatomically localized to the inferotemporal cortex and the fusiform gyrus. They further pointed out different regional brain activation, depending on treatment. While levodopa increased activity in areas associated with emotion processing, DBS hypoactivated them. The Stroop effect would hence be modulated by levodopa, but not by STN-DBS, "with this modulation being mainly mediated through the effect of each treatment on the recognition of facial emotion" ([@B76]).

Implications {#S4}
============

This review summarizes studies investigating the influence of STN-DBS on recognition of emotional facial expressions in PD patients. This summary provides double-sided results. The majority of studies either demonstrated worsening in the processing of at least single specific emotions or reported no changes in facial emotion recognition under STN-DBS. No study was able to show any ameliorations of facial emotion processing in patients when DBS was ON. Such improvements were visible only for non-facial material like written or spoken semantic stimuli and emotional prosody or non-facial pictorial stimuli ([@B24]; [@B22]; [@B106]; [@B117]).

However, these insights are of course biased by the fact that facial emotion processing is already deteriorated in PD patients, even before DBS surgery. Hence, it is rather complicated to define a baseline of facial emotion recognition that refers to "normal" performance in PD patients, and studies investigating DBS impact on this performance always underlie this bias. Furthermore, several methodological as well as clinical and individual factors contribute to different findings and exacerbate a final assertion concerning the efficacy of STN-DBS on facial emotion perception. These factors relate to experimental settings, selection criteria and choice of patients, additional dopaminergic medication next to DBS and its simultaneous intake or suspension, or settings regarding switching the stimulator ON or OFF. A general problem of all studies seems to comprise the recruitment and engagement of patients because all reported STN-DBS studies in this review present rather small sample sizes. With the exception of [@B5], who reported results of *N* = 30 patients, no other study was able to present data of more than 24 patients. Indeed, most studies showed results of less than 15 patients. Hence, a difficulty and challenge in the research of STN-DBS effects consist of the availability of data of an appropriate sample size to ensure validity and generalizability.

Finally, further possibly confounding or interacting factors have not been a subject of interest over studies, as for instance gender of patients, different cultural circles, living conditions, and other social factors of patients. For example, it is conceivable that single patients who live rather solitarily and secluded may undergo problems in facial emotion recognition due to inexperience and lack of contact with other people. This might concern particularly "socially and culturally defined" emotions, which were subject of studies assessing not (only) basic emotions but rather emotional gradations or social emotions like the Reading the Mind in the Eyes test ([@B11]). This might be taken into consideration in future investigations.

At any rate, studies demonstrated the possibility of deteriorated recognition of negative emotions out of faces, especially disgust or fear, after DBS surgery. This might have important implications for communication and social living for relatives, nurses, or caregivers of patients. Precautionary arrangements and accords should be entered to ensure optimal cooperation and well-being for patients.

Future studies might further aim to give more attention to the combined investigation of implicit and explicit emotional processing and the DBS influence on both. As this review could demonstrate, there is scarcely STN-DBS research investigating implicit emotional processing because most studies concentrated on emotion processing that is associated with thinking, categorizing, and reflecting.

Finally, it was recently postulated that "what is consistently reported as a group effect seems to be mainly driven by a small, but substantial subgroup of DBS-treated patients" ([@B56]; [@B41]). Effects of treatment may be small and specific to certain individuals. Thus, results should be regarded with respect to interindividual characteristics and intensities as well as to possible heterogeneous gains and losses from DBS.
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